论文部分内容阅读
神经内分泌肿瘤是一组异质性肿瘤,可具有不同的临床表现。此类肿瘤的影像学诊断富于挑战性,且不同病人有不同的成像需求。与正常组织比较,神经内分泌肿瘤细胞表面过度表达生长抑素受体,这为生长抑素类似物的多种临床应用提供了分子生物学基础。与CT或MRI相比,生长抑素受体显像应用99mTc-HYNIC-Tyr3-OCT或68Ga标记的生长抑素类似物作为单光子发射断层显像(SPECT)或正电子发射断层显像(PET)显像剂,在进行神经内分泌肿瘤分期和随访时能探查更多的病灶。迄今为止,生长抑素受体SPECT显像已广泛用于评估肿瘤的生长抑素受体表达水平及病人接受未标记或标记的生长抑素类似物治疗的可行性。68Ga标记的生长抑素类似物生长抑素受体PET显像敏感度高于SPECT显像,将来可能取代SPECT显像,成为神经内分泌肿瘤主要的分子影像诊断工具。
Neuroendocrine tumors are a heterogeneous group of tumors that can have different clinical manifestations. Imaging diagnosis of such tumors is challenging, and different patients have different imaging needs. Compared with normal tissues, somatostatin receptors are overexpressed on the surface of neuroendocrine tumor cells, which provides a molecular biological basis for many clinical applications of somatostatin analogs. Compared with CT or MRI, somatostatin receptor imaging using 99mTc-HYNIC-Tyr3-OCT or 68Ga labeled somatostatin analogues as single photon emission tomography (SPECT) or positron emission tomography (PET ) Imaging agent that can detect more lesions during staging and follow-up of neuroendocrine tumors. To date, somatostatin receptor SPECT imaging has been widely used to assess the tumor's expression of somatostatin receptors and the feasibility of patients receiving unlabeled or labeled somatostatin analogues. 68Ga labeled somatostatin analogues somatostatin receptor PET imaging sensitivity higher than SPECT imaging, the future may replace SPECT imaging, a neuroendocrine tumor molecular imaging diagnostic tool.